文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

纳米颗粒在神经退行性疾病中的治疗诊断应用。

Theranostic applications of nanoparticles in neurodegenerative disorders.

机构信息

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore,

Department of Animal Science, Centre for Pheromone Technology (CPT), Bharathidasan University, Tiruchirappalli, India.

出版信息

Int J Nanomedicine. 2018 Sep 20;13:5561-5576. doi: 10.2147/IJN.S149022. eCollection 2018.


DOI:10.2147/IJN.S149022
PMID:30271147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6154717/
Abstract

The preeminent treatments for neurodegenerative disease are often unavailable due to the poor accessibility of therapeutic drugs. Moreover, the blood-brain barrier (BBB) effectively blocks the transfer of cells, particles and large molecules, ie, drugs, across the brain. The most important challenge in the treatment of neurodegenerative diseases is the development of targeted drug delivery system. Theranostic strategies are known to combine therapeutic and diagnostic capabilities together. The aim of this review was to record the response to treatment and thereby improve drug safety. Nanotechnology offers a platform for designing and developing theranostic agents that can be used as an efficient nano-carrier system. This is achieved by the manipulation of some of the properties of nanoparticles (NPs), thereby enabling the attachment of suitable drugs onto their surface. The results provide revolutionary treatments by stimulation and thus interaction with targeted sites to promote physiological response with minimum side effects. This review is a brief discussion of the administration of drugs across the brain and the advantages of using NPs as an effective theranostic platform in the treatment of Alzheimer's, Parkinson's, epilepsy and Huntington's disease.

摘要

由于治疗药物的可及性差,神经退行性疾病的主要治疗方法往往无法实施。此外,血脑屏障(BBB)能有效地阻止细胞、颗粒和大分子(如药物)穿过大脑。神经退行性疾病治疗中最重要的挑战是开发靶向药物递送系统。治疗策略被认为是将治疗和诊断能力结合在一起。本综述的目的是记录治疗反应,从而提高药物安全性。纳米技术为设计和开发治疗诊断剂提供了一个平台,这些治疗诊断剂可以用作高效的纳米载体系统。这是通过操纵一些纳米颗粒(NPs)的特性来实现的,从而能够将合适的药物附着在它们的表面上。研究结果通过刺激并与靶向部位相互作用提供了革命性的治疗方法,从而促进生理反应,同时将副作用降到最低。本文简要讨论了药物在大脑中的传递,以及使用 NPs 作为一种有效的治疗诊断平台治疗阿尔茨海默病、帕金森病、癫痫和亨廷顿病的优势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/a52362bf5784/ijn-13-5561Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/9e9a3ddf93a0/ijn-13-5561Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/e5bec824a098/ijn-13-5561Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/51b892596f52/ijn-13-5561Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/1d5fb0d67e45/ijn-13-5561Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/5b48aaa7ddd2/ijn-13-5561Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/32fda943a5f1/ijn-13-5561Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/081d5d090e1f/ijn-13-5561Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/a52362bf5784/ijn-13-5561Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/9e9a3ddf93a0/ijn-13-5561Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/e5bec824a098/ijn-13-5561Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/51b892596f52/ijn-13-5561Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/1d5fb0d67e45/ijn-13-5561Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/5b48aaa7ddd2/ijn-13-5561Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/32fda943a5f1/ijn-13-5561Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/081d5d090e1f/ijn-13-5561Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/939d/6154717/a52362bf5784/ijn-13-5561Fig8.jpg

相似文献

[1]
Theranostic applications of nanoparticles in neurodegenerative disorders.

Int J Nanomedicine. 2018-9-20

[2]
A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics.

Int J Mol Sci. 2022-2-6

[3]
Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers.

Nanoscale. 2018-9-20

[4]
Application of Nanocomposites and Nanoparticles in Treating Neurodegenerative Disorders.

CNS Neurol Disord Drug Targets. 2024

[5]
Nanotechnological approaches for targeting amyloid-β aggregation with potential for neurodegenerative disease therapy and diagnosis.

Drug Discov Today. 2021-8

[6]
Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.

Curr Gene Ther. 2017

[7]
Nanoparticle-Based Technology Approaches to the Management of Neurological Disorders.

Int J Mol Sci. 2020-8-23

[8]
Current Strategies for Brain Drug Delivery.

Theranostics. 2018-2-5

[9]
Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.

Curr Drug Metab. 2017

[10]
Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.

Eur J Pharm Biopharm. 2020-1-23

引用本文的文献

[1]
Metallic Nanoparticles Applications in Neurological Disorders: A Review.

Int J Biomater. 2025-7-6

[2]
Theranostic advances and the role of molecular imprinting in disease management.

iScience. 2025-3-10

[3]
Macrophage membrane‒biomimetic nanoparticles target inflammatory microenvironment for epilepsy treatment.

Theranostics. 2024

[4]
Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration.

ACS Chem Neurosci. 2024-8-7

[5]
Targeted Treatment Strategies for Mitochondria Dysfunction: Correlation with Neurological Disorders.

Curr Drug Targets. 2024

[6]
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions.

Nano Converg. 2024-5-13

[7]
Theranostics: a multifaceted approach utilizing nano-biomaterials.

Discov Nano. 2024-2-26

[8]
Nanoneuroscience: Cutting-edge Approach for Disease Management.

Recent Pat Nanotechnol. 2024

[9]
Magnetic Resonance Imaging and Iron-oxide Nanoparticles in the era of Personalized Medicine.

Nanotheranostics. 2023

[10]
New strategies of neurodegenerative disease treatment with extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs).

Theranostics. 2023

本文引用的文献

[1]
Theranostic Probes for Targeting Tumor Microenvironment: An Overview.

Int J Mol Sci. 2017-5-11

[2]
Protein misfolding in neurodegenerative diseases: implications and strategies.

Transl Neurodegener. 2017-3-13

[3]
An Overview of Multimodal Neuroimaging Using Nanoprobes.

Int J Mol Sci. 2017-2-1

[4]
A theranostic agent for in vivo near-infrared imaging of β-amyloid species and inhibition of β-amyloid aggregation.

Biomaterials. 2016-4-1

[5]
Value of Functionalized Superparamagnetic Iron Oxide Nanoparticles in the Diagnosis and Treatment of Acute Temporal Lobe Epilepsy on MRI.

Neural Plast. 2016

[6]
Remote modulation of neural activities via near-infrared triggered release of biomolecules.

Biomaterials. 2015-6-25

[7]
Bovine serum albumin nanoparticles for delivery of tacrolimus to reduce its kidney uptake and functional nephrotoxicity.

Int J Pharm. 2015-4-10

[8]
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.

Biomaterials. 2015-1-15

[9]
Gold nanoparticle-antibody conjugates for specific extraction and subsequent analysis by liquid chromatography-tandem mass spectrometry of malondialdehyde-modified low density lipoprotein as biomarker for cardiovascular risk.

Anal Chim Acta. 2015-2-1

[10]
Selenium nanoparticles involve HSP-70 and SIRT1 in preventing the progression of type 1 diabetic nephropathy.

Chem Biol Interact. 2014-11-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索